The inhibitory effects of tulobuterol on ICAM-1 that we demonstrated in this study are consistent with previous reports that β2 agonists, such as fenoterol, salmeterol, and procaterol, reduce ICAM-1 expression in airway epithelial cells and fibroblast cells (Oddera et al. 1998; Silvestri et al. 2001; Yoshida et al. 2009; Yamaya et al. 2011) and may also be associated with the inhibitory effects of LABAs, such as formoterol and salmeterol, on the exacerbations of bronchial asthma and COPD (Pauwels et al. 1997; Calverley et al. 2007). The gene discussed is ICAM1; the disease is chronic obstructive pulmonary disease.